Adaptimmune Therapeutics plc (NASDAQ:ADAP) Sees Large Increase in Short Interest
Adaptimmune Therapeutics plc (NASDAQ:ADAP) experienced an 8.7% increase in short interest in December, totaling 5,500,000 shares by December 31. Analysts have adjusted price targets, with HC Wainwright lowering theirs from $4.00 to $3.50, and Mizuho from $3.00 to $1.50. The stock currently has a consensus rating of "Buy" and an average target price of $2.79. Institutional investors own 31.37% of the company, which has a market cap of $148.38 million and opened at $0.58 on Friday, down 1.7%.
Adaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 5,500,000 shares, an increase of 8.7% from the December 15th total of 5,060,000 shares. Based on an average daily volume of 2,120,000 shares, the short-interest ratio is currently 2.6 days.
Analysts Set New Price Targets
A number of analysts recently issued reports on ADAP shares. StockNews.com cut Adaptimmune Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Thursday, November 14th. HC Wainwright reduced their price objective on Adaptimmune Therapeutics from $4.00 to $3.50 and set a "buy" rating for the company in a research report on Thursday, November 14th. Mizuho reduced their price objective on Adaptimmune Therapeutics from $3.00 to $1.50 and set an "outperform" rating for the company in a research report on Wednesday, November 27th. Finally, Guggenheim reduced their price objective on Adaptimmune Therapeutics from $4.00 to $3.00 and set a "buy" rating for the company in a research report on Friday, November 15th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $2.79.
Check Out Our Latest Stock Report on ADAP
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the company. Fullcircle Wealth LLC acquired a new stake in shares of Adaptimmune Therapeutics in the third quarter valued at about $33,000. Vontobel Holding Ltd. boosted its stake in Adaptimmune Therapeutics by 230.8% during the 3rd quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 30,000 shares during the period. GSA Capital Partners LLP bought a new stake in Adaptimmune Therapeutics during the 3rd quarter valued at approximately $95,000. Virtu Financial LLC boosted its stake in Adaptimmune Therapeutics by 27.5% during the 3rd quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company's stock valued at $96,000 after purchasing an additional 21,769 shares during the period. Finally, Jane Street Group LLC boosted its stake in Adaptimmune Therapeutics by 130.4% during the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company's stock valued at $166,000 after purchasing an additional 98,581 shares during the period. Institutional investors own 31.37% of the company's stock.
Adaptimmune Therapeutics Trading Down 1.7 %
NASDAQ:ADAP opened at $0.58 on Friday. The company's 50 day moving average is $0.64 and its 200-day moving average is $0.90. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62. Adaptimmune Therapeutics has a 12 month low of $0.53 and a 12 month high of $2.05. The firm has a market cap of $148.38 million, a price-to-earnings ratio of -2.64 and a beta of 2.24.
About Adaptimmune Therapeutics
(Get Free Report)Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
Featured Articles
- Five stocks we like better than Adaptimmune Therapeutics
- Where Do I Find 52-Week Highs and Lows?
- Earn High Dividends With 2 Top REITs Set to Perform in 2025
- ESG Stocks, What Investors Should Know
- Oilfield Leader SLB: An AI Name You Need to Know
- Canada Bond Market Holiday: How to Invest and Trade
- Top ETFs That Beat the Market in 2024 and Could Do It Again
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Adaptimmune Therapeutics Right Now?
Before you consider Adaptimmune Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptimmune Therapeutics wasn't on the list.
While Adaptimmune Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
